Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83

Mark R. Schleiss, Nigel Bourne, Nancy J. Jensen, Fernando Bravo, David I. Bernstein

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Vaccines are needed for control of congenital human cytomegalovirus (HCMV) infection. Although the species-specificity of cytomegaloviruses precludes preclinical evaluation of HCMV vaccines in animal models, the guinea pig cytomegalovirus (GPCMV), which causes disease in utero, is a relevant model for the study of vaccines against congenital infection. We investigated whether DNA vaccines that target two GPCMV proteins, glycoprotein B (gB) and UL83 (pp65), are capable of eliciting immune responses in vivo. After cloning each gene into an expression vector, DNA was delivered by intramuscular inoculation and by pneumatic epidermal delivery. In Swiss-Webster mice, anti-gB titers were significantly higher alter epidermal delivery. After epidermal inoculation in guinea pigs, all gB- immunized animals (n = 6) had antibody responses comparable to those induced by natural infection. Viral neutralization titers ranged from 1:64 to greater than 1:128. A GPCMV UL83 DNA vaccine also elicited an antibody response in all immunized guinea pigs (n = 6) after epidermal administration. Immunoprecipitation and Western blot assays confirmed that immune sera were immunoreactive with virion-associated UL83 and gB proteins. We conclude that DNA vaccines against GPCMV structural proteins are immunogenic, and warrant further investigation in the guinea pig model of congenital CMV infection.

Original languageEnglish (US)
Pages (from-to)155-167
Number of pages13
JournalViral Immunology
Volume13
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Roseolovirus
DNA Vaccines
Glycoproteins
Guinea Pigs
Antibody Formation
Cytomegalovirus Vaccines
Vaccines
Infection
Species Specificity
Cytomegalovirus Infections
Cytomegalovirus
Immunoprecipitation
Virion
Organism Cloning
Immune Sera
Animal Models
Western Blotting
Gene Expression
Simplexvirus glycoprotein B
IgA receptor

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. / Schleiss, Mark R.; Bourne, Nigel; Jensen, Nancy J.; Bravo, Fernando; Bernstein, David I.

In: Viral Immunology, Vol. 13, No. 2, 2000, p. 155-167.

Research output: Contribution to journalArticle

Schleiss, Mark R. ; Bourne, Nigel ; Jensen, Nancy J. ; Bravo, Fernando ; Bernstein, David I. / Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. In: Viral Immunology. 2000 ; Vol. 13, No. 2. pp. 155-167.
@article{8efbca9b820d44658c53a1637ee05909,
title = "Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83",
abstract = "Vaccines are needed for control of congenital human cytomegalovirus (HCMV) infection. Although the species-specificity of cytomegaloviruses precludes preclinical evaluation of HCMV vaccines in animal models, the guinea pig cytomegalovirus (GPCMV), which causes disease in utero, is a relevant model for the study of vaccines against congenital infection. We investigated whether DNA vaccines that target two GPCMV proteins, glycoprotein B (gB) and UL83 (pp65), are capable of eliciting immune responses in vivo. After cloning each gene into an expression vector, DNA was delivered by intramuscular inoculation and by pneumatic epidermal delivery. In Swiss-Webster mice, anti-gB titers were significantly higher alter epidermal delivery. After epidermal inoculation in guinea pigs, all gB- immunized animals (n = 6) had antibody responses comparable to those induced by natural infection. Viral neutralization titers ranged from 1:64 to greater than 1:128. A GPCMV UL83 DNA vaccine also elicited an antibody response in all immunized guinea pigs (n = 6) after epidermal administration. Immunoprecipitation and Western blot assays confirmed that immune sera were immunoreactive with virion-associated UL83 and gB proteins. We conclude that DNA vaccines against GPCMV structural proteins are immunogenic, and warrant further investigation in the guinea pig model of congenital CMV infection.",
author = "Schleiss, {Mark R.} and Nigel Bourne and Jensen, {Nancy J.} and Fernando Bravo and Bernstein, {David I.}",
year = "2000",
language = "English (US)",
volume = "13",
pages = "155--167",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83

AU - Schleiss, Mark R.

AU - Bourne, Nigel

AU - Jensen, Nancy J.

AU - Bravo, Fernando

AU - Bernstein, David I.

PY - 2000

Y1 - 2000

N2 - Vaccines are needed for control of congenital human cytomegalovirus (HCMV) infection. Although the species-specificity of cytomegaloviruses precludes preclinical evaluation of HCMV vaccines in animal models, the guinea pig cytomegalovirus (GPCMV), which causes disease in utero, is a relevant model for the study of vaccines against congenital infection. We investigated whether DNA vaccines that target two GPCMV proteins, glycoprotein B (gB) and UL83 (pp65), are capable of eliciting immune responses in vivo. After cloning each gene into an expression vector, DNA was delivered by intramuscular inoculation and by pneumatic epidermal delivery. In Swiss-Webster mice, anti-gB titers were significantly higher alter epidermal delivery. After epidermal inoculation in guinea pigs, all gB- immunized animals (n = 6) had antibody responses comparable to those induced by natural infection. Viral neutralization titers ranged from 1:64 to greater than 1:128. A GPCMV UL83 DNA vaccine also elicited an antibody response in all immunized guinea pigs (n = 6) after epidermal administration. Immunoprecipitation and Western blot assays confirmed that immune sera were immunoreactive with virion-associated UL83 and gB proteins. We conclude that DNA vaccines against GPCMV structural proteins are immunogenic, and warrant further investigation in the guinea pig model of congenital CMV infection.

AB - Vaccines are needed for control of congenital human cytomegalovirus (HCMV) infection. Although the species-specificity of cytomegaloviruses precludes preclinical evaluation of HCMV vaccines in animal models, the guinea pig cytomegalovirus (GPCMV), which causes disease in utero, is a relevant model for the study of vaccines against congenital infection. We investigated whether DNA vaccines that target two GPCMV proteins, glycoprotein B (gB) and UL83 (pp65), are capable of eliciting immune responses in vivo. After cloning each gene into an expression vector, DNA was delivered by intramuscular inoculation and by pneumatic epidermal delivery. In Swiss-Webster mice, anti-gB titers were significantly higher alter epidermal delivery. After epidermal inoculation in guinea pigs, all gB- immunized animals (n = 6) had antibody responses comparable to those induced by natural infection. Viral neutralization titers ranged from 1:64 to greater than 1:128. A GPCMV UL83 DNA vaccine also elicited an antibody response in all immunized guinea pigs (n = 6) after epidermal administration. Immunoprecipitation and Western blot assays confirmed that immune sera were immunoreactive with virion-associated UL83 and gB proteins. We conclude that DNA vaccines against GPCMV structural proteins are immunogenic, and warrant further investigation in the guinea pig model of congenital CMV infection.

UR - http://www.scopus.com/inward/record.url?scp=0033936513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033936513&partnerID=8YFLogxK

M3 - Article

C2 - 10892996

AN - SCOPUS:0033936513

VL - 13

SP - 155

EP - 167

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 2

ER -